WHEREAS, NF represents three genetically distinct disorders;
and
WHEREAS, Type 1 (NF1), classified as a tumor predisposition
syndrome, is a progressive disorder usually diagnosed in
childhood; and
WHEREAS, Diagnosis is based on physical findings relating to
a child's skin, eyes, bones and brain; and
WHEREAS, The presence of internal and external tumors and
areas of abnormal skin color characterize NF1; and
WHEREAS, Combination drugs may moderate NF1-linked drug
resistance mechanisms; and
WHEREAS, Type 2 (NF2) causes peripheral neuropathy and
deteriorating balance and hearing; and
WHEREAS, Slow-growing tumors on cranial nerves distinguish
NF2; and
WHEREAS, Early onset of NF2 symptoms has an adverse effect on
long-term survival; and
WHEREAS, Schwannomatosis (SWN), the third type, has two known
causative genes which give rise to benign tumors; and
WHEREAS, SWN induces intense neuropathic pain, numbness and
weakness; and
WHEREAS, No targeted therapies reverse NF expression; and
WHEREAS, Primary care providers, genetic counselors, physical
therapists, radiation therapists and behavioral therapists
contribute to patient-centered care teams; and
WHEREAS, NF treatment plans may include pain control,
chemotherapy and surgical resection of tumors; and
WHEREAS, Education and counseling along with monitoring of
local, systemic and chronic symptoms and neurocognitive
impairments are other elements of NF care; and
20190SR0123PN0744 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30